Plasma miR-126 as a potential marker predicting major adverse cardiac events in dual antiplatelet-treated patients after percutaneous coronary intervention

Yu, Xiang; Chen, Jiyan; Zheng, Zhiwei; Wu, Hong; Liu, Liwen; Zhang, Zhiwei; Chen, Zhihong; Lin, Qian; Han, Yaling; Zhong, Shilong

doi:10.4244/eijv9i5a90

Cited by 34 publications

(21 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Third, HTPR on clopidogrel and aspirin associated with lower miR-223 in platelets [7] and plasma [8]. On the other hand, miR-223 was unrelated to a 12-month prognosis after coronary angioplasty [19] and platelet function was independent of miR-223 in mice [20].…”

Section: Discussionmentioning

confidence: 99%

Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: A preliminary report

et al. 2014

View full text Add to dashboard Cite

Decreased plasma levels of microRNA-223 (miR-223), predominantly of platelet origin, were proposed as a surrogate marker of efficacy of antiplatelet therapy. However, higher on-treatment platelet reactivity was associated with lower plasma miR-223 in patients with coronary artery disease (CAD) on dual antiplatelet therapy (DAPT) including clopidogrel and aspirin. Our aim was to compare plasma miR-223 and platelet reactivity in CAD patients on DAPT with newer P2Y12 antagonists vs. clopidogrel. We studied 21 men with CAD admitted to our centre owing to a non-ST-elevation acute coronary syndrome, and with an uncomplicated hospital course. From the day of admission, the patients were receiving either clopidogrel (n = 11) or prasugrel/ticagrelor (n = 10) in addition to aspirin. Before discharge, miR-223 expression in plasma was estimated by quantitative polymerase chain reaction using the comparative Ct method relative to miR-16 as an endogenous control. Multiple electrode aggregometry was used to assess platelet aggregation in response to adenosine diphosphate (ADP). ADP-induced platelet reactivity was decreased in the patients treated with prasugrel or ticagrelor compared with those on clopidogrel (mean ± SD: 139 ± 71 vs. 313 ± 162 arbitrary units [AU]*min, p = 0.006), due to a more potent antiplatelet activity of the novel P2Y12 antagonists. Consequently, six out of seven patients in the lower tertile of the ADP-induced platelet aggregation were treated with the newer P2Y12 blockers, whereas six out of seven patients in the upper tertile were on clopidogrel. Plasma miR-223 was elevated with decreasing platelet reactivity (Spearman's rho = -0.52; p = 0.015 for trend), being significantly higher in the lower tertile of the ADP-induced platelet aggregation (median [range]: 1.06 [0.25-2.31]) vs. the upper tertile (0.20 [0.13-2.30]) (p = 0.04). In conclusion, our preliminary results argue against the notion of low plasma miR-223 as a marker of platelet responsiveness to DAPT. On the contrary, more potent platelet inhibition associated mainly with newer P2Y12 antagonists appears to coincide with higher miR-223 relative to the subjects with attenuated responsiveness to DAPT.

show abstract

Section: Discussionmentioning

confidence: 99%

Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: A preliminary report

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In the atherosclerotic mice models induced by ApoE-/-, miR-223 upregulation has been found to abrogate atherosclerosis development [15]. Yu et al have proposed that plasma miR-126 could be considered as a potent marker for the prediction of major adverse cardiovascular events [16]. Furthermore, the ability of miR-126 to differentiate patients with atherosclerosis patients from healthy people has been demonstrated via a ROC curve with high sensitivity and speci city [17].…”

Section: Discussionmentioning

confidence: 99%

Relationship between serum microRNA-223 and microRNA-126 and plaque stability in patients with carotid atherosclerosis

zhang¹,

J²,

Ma³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Numerous researches have demonstrated the essential functions of microRNAs (miRNAs) in cardiovascular disease. Herein, we want to probe into the roles of miR-126 and miR-223 in the prediction of plaque stability of carotid atherosclerosis (CA). Methods First, miRNA microarray was performed to analyze the differentially expressed miRNA in serum of normal controls and CA patients. Next, the differential expression of miR-223 and miR-126 in CA was verified and the correlations of their expression levels with plaque stability-related factors were analyzed. Then, the predictive efficacy of miR-223 and miR-126 on plaque stability was analyzed by receiver operating characteristic curve, then the targeting relationships of miR-223 and miR-126 with COX2 were verified by online prediction and luciferase activity assay. Finally, the relationship between COX2 expression and CA plaque stability was analyzed. Results Expression levels of miR-223 and miR-126 were decreased in the serum of CA patients and they had good diagnostic efficacy for CA. Additionally, we found that the expression levels of miR-223 and miR-126 in the serum of CA patients with unstable plaque were lower than those with stable plaque. miR-223 and miR-126 were negatively correlated with plaque instability-related indicators, while COX2, a direct target gene of miR-223 and miR-126, was positively related to plaque instability-related indicators. Conclusion This study indicates that miR-223 and miR-126 are lowly expressed in serum of CA patients, which can be used as a clinical indicator for predicting the plaque stability in CA patients.

show abstract

“…Anti-miRNA-126 transfection markedly impaired the capacity of angiogenic early outgrowth cells (EOCs) from healthy subjects to improve cardiac function (cardiac neovascularization and function) [70]. In this way, plasma miRNA-126 could be a potential marker for predicting major adverse cardiac events in patients after percutaneous coronary intervention [71].…”

Section: Mirna-126mentioning

confidence: 99%

Platelet miRNAs and cardiovascular diseases

2015

View full text Add to dashboard Cite

Plasma miR-126 as a potential marker predicting major adverse cardiac events in dual antiplatelet-treated patients after percutaneous coronary intervention

Abstract: Based on these results, we suggest that plasma miR-126 could be a potential marker for predicting major adverse cardiac events in patients after PCI.

Cited by 34 publications

References 21 publications

Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: A preliminary report

Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: A preliminary report

Relationship between serum microRNA-223 and microRNA-126 and plaque stability in patients with carotid atherosclerosis

Platelet miRNAs and cardiovascular diseases

Contact Info

Product

Resources

About